Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
Della Corte CM, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, Troiani T, Martinelli E, Wang J, Byers L, Morgillo F, Ciardiello F.
Della Corte CM, et al. Among authors: tuccillo c.
J Exp Clin Cancer Res. 2022 Mar 26;41(1):109. doi: 10.1186/s13046-022-02332-2.
J Exp Clin Cancer Res. 2022.
PMID: 35346313
Free PMC article.